Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Pro Medicus Limited ( (AU:PME) ).
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program, which involves the repurchase of its ordinary fully paid shares. As of December 12, 2025, the company has bought back a total of 42,164 shares, including 1,025 shares acquired on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging software and services to medical professionals. The company focuses on delivering innovative solutions for radiology departments and imaging centers, enhancing diagnostic capabilities and operational efficiencies.
Average Trading Volume: 175,463
Technical Sentiment Signal: Buy
Current Market Cap: A$25.87B
See more insights into PME stock on TipRanks’ Stock Analysis page.